RT Journal Article
SR Electronic
T1 Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.18.20214841
DO 10.1101/2020.10.18.20214841
A1 Alayo, Quazim A.
A1 Khatiwada, Aava
A1 Patel, Anish
A1 Zulfiqar, Maria
A1 Gremida, Anas
A1 Gutierrez, Alexandra
A1 Rood, Richard P.
A1 Ciorba, Matthew A.
A1 Christophi, George
A1 Deepak, Parakkal
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.18.20214841.abstract
AB Background One therapeutic option with limited data among patients with active moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD) despite biologic monotherapy is using a combination of a biologic with Tofacitinib (TBT). Our aim was to examine the effectiveness and safety of TBT in this subset of patients.Methods Data of IBD patients at 2 referral centers on TBT were extracted. The primary outcome was clinical response (>50% reduction in symptoms) at week 8 and/or 16 determined by Physician Global Assessment. Secondary outcome was clinical remission (resolution of symptoms), corticosteroid-free clinical response and remission, normalization of CRP and endoscopic/radiographic response and remission. Adverse events (AEs) including any abnormal lipid profile or surgical complications were also assessed.Results Thirty-five patients (25UC, 10CD) were included. Biologics combined with tofacitinib were vedolizumab (68.6%), ustekinumab (17.1%), and infliximab (14.3%) and the median follow-up duration was 4 months. A majority (57.2%) had failed at least two biologics prior to starting TBT. At weeks 8 and/or 16, 37.1% achieved clinical response with 5.7% in clinical remission. Among the 23 patients with endoscopically/radiographically active disease at baseline, 56.5% had endoscopic/radiographic response and 34.8% achieved remission. Three AEs occurred in 2 (5.7%) patients, with an IR of 20.5 (15.0–47.2)/100PYF. No VTE and herpes zoster was reported.Conclusions TBT is effective at inducing endoscopic/radiographic response and a modest clinical response in UC and CD patients with active clinical symptoms despite prior biologic monotherapy. No new safety signals were detected beyond those reported with tofacitinib monotherapy.Competing Interest StatementQuazim A. Alayo, Aava Khatiwada, Anish Patel, Maria Zulfiqar, Anas Gremida, George P. Christophi disclose no relevant conflicts of interest. Parakkal Deepak: PD has served as a consultant or advisory board member for Janssen, Pfizer, Celgene, Arena, Prometheus; research grants from Takeda. Alexandra Gutierrez: AG has served as a speaker for Janssen. Richard Rood: RR is an advisor to Coloplast Corporation and has received research support from Gilead and Eli Lilly Matthew A. Ciorba: MAC has done consultancy for Takeda, Pfizer and Prometheus labs and has been on the speaker bureau for AbbVie, Pfizer, Takeda, and UCB. Research support from Incyte. Funding StatementParakkal Deepak is supported by a Junior Faculty Development Award from the American College of Gastroenterology. Matthew A. Ciorba is supported by DK109384, a Crohn's and Colitis Foundation Daniel H Present Senior Research Award (Ref. 370763) and philanthropic support from the Givin' it all for Guts Foundation (https://givinitallforguts.org) and the Lawrence C. Pakula MD IBD Research Innovation and Education Fund. Anas Gremida is supported by the Lawrence C. Pakula, MD Advanced IBD Fellowship grant. Additional grant support for the REDCap database was provided by the Clinical and Translational Science Award (UL1 TR000448) and Siteman Cancer Center Support Grant (P30-CA091842).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Institutional Review Boards (IRB) of both institutions and was conducted in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/ABIDTwice dailyCDCrohn’s diseaseCOVID-19Coronavirus disease 2019CRPC-Reactive proteinDBTDual biologic therapyDVTDeep venous thrombosisHASTEHalf-Fourier Acquisition Single-Shot Turbo-Spin-EchoHZVHerpes Zozter VirusIBDInflammatory bowel diseasesIFX-TBTInfliximab plus TofacitinibIQRInterquartile rangeIRIncidence ratesIRBInstitutional review boardJAKJanus KinaseMACEMajor adverse cardiovascular eventMREMagnetic resonance enterographyPGAPhysician Global AssessmentPYFPatient-years of follow-upSES-CDSimple Endoscopic Score for Crohn’s DiseasesMARIASimplified Magnetic resonance index of activityTBTTofacitinib plus Biologic TherapyUCUlcerative colitisUST-TBTUstekinumab plus TofacitinibVTEVenous thromboembolismVDZ-TBTVedolizumab plus TofacitinibXRExtended release